Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Colorcon
Mallinckrodt
Baxter

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PAMELOR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pamelor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00062738 ↗ Treatment of Depression in Parkinson's Disease Trial Completed GlaxoSmithKline Phase 2 2003-06-01 The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.
NCT00062738 ↗ Treatment of Depression in Parkinson's Disease Trial Completed Rutgers, The State University of New Jersey Phase 2 2003-06-01 The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.
NCT00547703 ↗ Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia Terminated Cleveland Clinic Florida N/A 2008-02-01 The purpose of this study is to determine if use of Nortriptyline will improve symptoms and quality of life in patients who have nonulcer dyspepsia.
NCT00547703 ↗ Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia Terminated The Cleveland Clinic N/A 2008-02-01 The purpose of this study is to determine if use of Nortriptyline will improve symptoms and quality of life in patients who have nonulcer dyspepsia.
NCT00742573 ↗ Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics Completed National Institute of Mental Health (NIMH) Phase 2 2008-08-01 This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
NCT00742573 ↗ Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics Completed New York State Psychiatric Institute Phase 2 2008-08-01 This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pamelor

Condition Name

Condition Name for Pamelor
Intervention Trials
Depression 2
Major Depressive Disorder 2
Geriatric Depression 1
Idiopathic Gastroparesis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pamelor
Intervention Trials
Depression 5
Depressive Disorder 4
Depressive Disorder, Major 3
Cognitive Dysfunction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pamelor

Trials by Country

Trials by Country for Pamelor
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pamelor
Location Trials
Washington 1
Maryland 1
Texas 1
Pennsylvania 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pamelor

Clinical Trial Phase

Clinical Trial Phase for Pamelor
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pamelor
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pamelor

Sponsor Name

Sponsor Name for Pamelor
Sponsor Trials
National Institute of Mental Health (NIMH) 2
Rutgers, The State University of New Jersey 1
Centre for Addiction and Mental Health 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pamelor
Sponsor Trials
Other 9
NIH 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.